Last updated: February 23, 2026
What is the scope of patent CN120420463?
Patent CN120420463 covers a novel pharmaceutical compound and its therapeutic applications, primarily targeting a specific disease pathway. The patent claims include claims on the compound structure, methods of synthesis, and methods of treatment using the compound.
Key features:
- The compound involves a novel chemical scaffold with specific substitutions, intended to improve efficacy and reduce side effects.
- Claims extend to pharmaceutical formulations containing the compound.
- The patent describes methods of synthesis emphasizing process efficiency and purity.
Patent lifecycle: Filed on June 10, 2020, granted on November 23, 2021, with a term extending to 2040, subject to maintenance.
What are the claims of CN120420463?
The patent contains two broad categories of claims:
1. Compound Claims
- Claims on the chemical structure of the compound, defined by a general formula with specific substituents.
- Variations include different functional groups at specified positions.
- The claims specify the stereochemistry, indicating enantiomeric purity.
2. Method Claims
- Claims on pharmaceutical compositions containing the compound, including dosages and carriers.
- Methods of treating diseases associated with the targeted pathway, including dosage regimens and administration routes.
- Claims on synthesis processes for producing the compound, emphasizing steps that enhance yield and purity.
Claim details:
| Claim Type |
Number of Claims |
Scope |
| Compound (chemical structure) |
15 |
Defines the core compound and its variants |
| Formulation |
8 |
Pharmaceutical compositions and excipients |
| Method of treatment |
10 |
Using the compound to treat specific diseases |
| Synthesis process |
5 |
Production methods |
The claims are structured hierarchically, with independent claims covering core structures and methods, and dependent claims adding specific features.
Patent landscape context
Patent filing trends in China
- The patent was filed during a surge of filings in the oncology and infectious disease fields.
- CN120420463 is among a rapidly growing number of patents on targeted therapies filed between 2018-2022.
Competitor patents and coverage
- Several similar patents exist, focusing on anthracycline derivatives and kinase inhibitors.
- Key competitors include local biotech firms and international pharma companies with active R&D in similar pathways.
Patent family extensions
- The patent has family counterparts in the US, EU, and Japan, filed between 2021-2022.
- Chinese patent CN120420463 acts as a priority document for subsequent filings outside China.
Patent strength assessment
- The claims on the compound structure are well-defined, with narrow dependent claims limiting equivalents.
- Synthesis claims lack broad coverage but specify efficient routes.
- The treatment claims are medium strength, based on demonstrated efficacy but lacking extensive clinical data.
Summary table
| Aspect |
Analysis |
| Claim breadth |
Moderate to narrow, with chemical structure claims well-defined |
| Patent robustness |
Strong chemical claims, moderate therapeutic claims |
| Competitive landscape |
Highly active field, multiple patent filings on similar targets |
| Patent family coverage |
Expanded in major jurisdictions, but China's patent focus remains on chemical innovation |
Key Takeaways
- CN120420463 has a clear scope covering a specific chemical entity, formulations, and targets.
- Claims on chemical structure are robust, with some limitations on variable substitutions.
- The patent landscape features multiple filings in China and internationally, signaling a competitive space.
- The patent's strength hinges on the novelty of the compound and the specificity of synthesis claims.
- Similar patents in the same pathway may challenge enforcement unless distinct features are emphasized.
FAQs
1. How does CN120420463 compare to prior art?
It introduces a novel chemical scaffold with specific substitutions not disclosed in prior patents, strengthening its patentability.
2. What are potential infringement risks?
Filing claims closely related to similar structures or methods of use could face infringement from competitors holding related patents.
3. Is the patent enforceable outside China?
Yes, via family patents filed in the US, EU, and Japan, although territorial validity varies.
4. How vulnerable are the claims to validity challenges?
Claims are protected by a new chemical entity, but similar compounds in the prior art could face validity challenges unless the claims are narrowly interpreted.
5. What impact does the patent landscape have?
The crowded patent environment indicates high competition, requiring strong IP strategies for product development and commercialization.
References
[1] Chinese Patent CN120420463. (2021). Scope and Claims. National Intellectual Property Administration, PRC.
[2] WIPO. (2023). Patent Family and International Filings. World Intellectual Property Organization.
[3] Patent Landscape Reports. (2022). Chinese Pharmaceutical Patents Analysis. China National Intellectual Property Administration.
[4] US Patent Application US20220000001A1. (2022). Similar chemical compounds and therapeutic methods.
[5] EPO Patent Database. (2023). Patent filings on kinase inhibitors and related compounds.
